Harrow, Inc. (HROW)

10.43 +0.24 (+2.36%) At close: 04:00PM EDT

Harrow, Inc.

102 Woodmont Boulevard
Suite 610
Nashville, TN 37205
United States
615 733 4730
https://www.harrow.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 315

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Mark L. Baum J.D.	CEO & Chairman of the Board	1.11M	N/A	1972
Mr. Andrew R. Boll C.F.A., C.M.A.	CFO & Corporate Secretary	698.22k	N/A	1982
Mr. John P. Saharek MBA	Chief Commercial Officer	669.4k	N/A	1960
Dr. Dennis E Saadeh Pharm.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Jamie Webb	Director of Communications & Investor Relations	N/A	N/A	N/A
Mr. Brett A. Burrell	Vice President of Legal & Compliance	N/A	N/A	N/A
Ms. Kim Barratt	Chief of Staff	N/A	N/A	N/A
Dr. Mark A. Mannebach Ph.D., R.Ph.	Head of Regulatory Affairs & Pharmacovigilance	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Corporate governance

Harrow, Inc.’s ISS governance QualityScore as of 29 April 2024 is 5. The pillar scores are Audit: 3; Board: 7; Shareholder rights: 3; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.